안녕하세요. 다안 암 연구실의 조병철 교수님, 윤미란 박사님(공동 교신저자), 이은지 학생(제 1저자)께서 참여하신 논문이, Clinical Cancer Research에 게재되어 공지드립니다. (ManuscriptTitle:Discovery of a novel potent EGFR inhibitor against EGFR activating mutations and on-target resistance in NSCLC) 논문 작성으로 연일 연구에 매진하신 선생님들께많은 격려와 축하 부탁드립니다!감사합니다.
안녕하세요.다안 암 연구실입니다.다안 암 연구실의 임선민 교수님/이기쁨 교수님(제1저자)께서 참여하신 논문이, Journal of Clinical Oncology Oncology Practice에 출판되어 공지드립니다.(ManuscriptTitle:Path less Traveled: Targeting Rare Driver Oncogenes in Non–Small-Cell Lung Cancer) 논문 작성으로 연일 연구에 매진하신 교수님들께,많은 격려와 축하 부탁드립니다! 감사합니다.
안녕하세요. 다안 암 연구실의임선민 교수님(제1저자/교신저자)께서 참여하신 논문이, Clinical Cancer Research에 게재되어 공지드립니다. (ManuscriptTitle:BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer)
안녕하세요. 다안 암 연구실의 임선민 교수님, 윤미란 박사님(공동교신저자), 오승연 학생(제1저자)께서 참여하신 논문이, Clinical Cancer Research(IF: 13.801)에 승인되어 공지드립니다. (Manuscript Title: Preclinical study of a biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC…
다안 암 연구실의 김석영 선생님(제 1저자), 조병철 교수님, 허성구 박사님(교신저자)께서 참여하신 논문이,Clinical Cancer Research에 최종 Publish 되어 공지드립니다. (Full Title: Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma)
다운로드하려면 클릭
AbstractIntroduction:Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that is approved for the use ofEGFR-mutant non-small cell lung cancer (NSCLC) patients. In this study, we investigated the acquired resistance mechanisms in NSCLC patients and patient-derived preclinical mode…
AbstractThe development of cancer therapies using monoclonal antibodies has been successful during the last 30 years. Recently much progress was achieved with technologies involving bispecific and multi-specific antibodies. Bispecific antibodies (BsAbs) are antibodies that bind two distinct epitopes…
AbstractObjective:Anti-programmed death (PD)-1 therapy confers sustainable clinical benefits for patients with non-small-cell lung cancer (NSCLC), but only some patients respond to the treatment. Various clinical characteristics, including the PD-ligand 1 (PD-L1) level, are related to the anti-PD-1 …
